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Abstract
Background—To determine the cost-effectiveness of In-Home Cognitive Behavioral Therapy 
(IH-CBT) for low-income mothers enrolled in a home visiting program.
Methods—A cost-utility analysis was conducted using results from a clinical trial of IH-CBT 
and standard of care for depression derived from the literature. A probabilistic, patient-level 
Markov model was developed to determine Quality Adjusted Life Years (QALYs). Costs were 
determined using the Medical Expenditure Panel Survey. A three-year time horizon and payer 
perspective were used. Sensitivity analyses were employed to determine robustness of the model.
Results—IH-CBT was cost-effective relative to standard of care. IH-CBT was expected to be 
cost-effective at a three-year time horizon 99.5%, 99.7%, and 99.9% of the time for willingness-
to-pay thresholds of US$25,000, US$50,000, and US$100,000, respectively. Patterns were upheld 
at one-year and five-year time horizons. Over the three-year time horizon, mothers receiving IH-
CBT were expected to have 345.6 fewer days of depression relative to those receiving standard 
home visiting and treatment in the community.
Conclusions—IH-CBT is a more cost-effective treatment for low-income, depressed mothers 
than current standards of practice. These findings add to the growing literature demonstrating the 
cost-effectiveness of CBT for depression, and expand it to cover new mothers. From a payer 
perspective, IH-CBT is a sound option for treatment of depressed, low-income mothers. 
Limitations include a restricted time horizon and estimating of standard of care costs.
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1. Introduction
Major depressive disorder (MDD) is a disabling psychiatric condition, particularly in new 
mothers (O’Hara and Wisner, 2014). The symptoms of depression, including fatigue, 
anhedonia, and feelings of worthlessness, contribute to functional impairments in parenting 
and nurturing. These, in turn, increase the risk for maladjustment and poor developmental 
outcomes in offspring (Goodman et al., 2011). The onset of depression in new mothers often 
begins during pregnancy and extends episodically through the child rearing years. Banti et 
al. (2011) found that 12.4% of women met criteria for minor or major depression during 
pregnancy. Wisner et al. (2013) reported that 14.0% of mothers exceeded clinical cutoffs on 
a screen for depression administered during 4–6 weeks postpartum. Another study examined 
self-reported depression measured at 10 time points over the first 12 years, reporting that 
20.7% exceeded clinical cutoffs on average at one or more time points (Campbell et al., 
2009). Low-income mothers are especially at risk for developing depression and for 
experiencing the deleterious consequences of the condition (Goyal et al., 2010).
1.1 Costs of depression in low-income mothers
In addition to its human costs, depression in mothers has financial implications as well. In 
depressed adults, Greenberg et al. (2003) found that, in 2000, the economic burden of 
depression was US$83.1 billion. These reflect costs in health care, labor productivity, and 
mortality. Documented costs associated with maternal depression include increased 
utilization of health care services (Greenberg et al., 2003), increased rates of prematurity and 
low birthweight that require specialized care of children (Jarde et al., 2016), and additional 
health and related costs (Smith and Smith, 2010). Ammerman et al. (2016) examined health 
care and labor productivity costs in low-income, depressed mothers. They documented US
$2.41 billion in added direct and indirect costs annually in depressed mothers relative to 
their non-depressed counterparts. Delivery of effective treatments to depressed mothers who 
are at highest risk is essential to facilitate recovery, mitigate impact on offspring, and reduce 
costs to payers and society.
1.2 Treatment of depression in low-income mothers in home visiting
Providing treatment to low-income mothers with depression is complicated by barriers to 
identification, engagement, and retention. Recently, there have been calls to identify, screen, 
and treat mothers in the context of other programs that provide services to low-income 
mothers as a way to overcome these barriers (O’Connor et al., 2016). Early childhood 
prevention programs, in particular home visiting (Ammerman, 2016), provide a promising 
opportunity for delivery of effective treatment. Home visiting programs, both targeted and 
universal, are widely available in many developed countries (Engle et al., 2007). Home 
visiting programs seek to support new mothers in their roles as parents. They strive to teach 
parenting skills and promote a safe and nurturing environment for children in order to 
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optimize developmental outcomes. Home visiting services are voluntary, and many routinely 
screen for depression. Research suggests that up to 61% of mothers in home visiting 
experience clinically elevated levels of depression during the course of service (Ammerman 
et al., 2010). A subgroup of mothers experiences a persistently high level of symptoms 
throughout the first years of the child’s life (Teeters et al., 2016). Home visiting alone 
appears to have little to no impact on depressive symptoms in mothers participating in home 
visiting (Ammerman et al., 2010), thus warranting direct treatment as the most appropriate 
response in most cases.
Ammerman et al. (2011) adapted cognitive behavioral therapy to meet the needs of 
depressed, low-income mothers enrolled in home visiting. In-Home Cognitive Behavioral 
Therapy (IH-CBT) is implemented by therapists who provide treatment concurrently with 
ongoing home visiting. IH-CBT uses strategies that facilitate engagement, make content 
relevant to the needs of low-income mothers, allow delivery in the home, and promote a 
collaborative relationship between the therapist and home visitor in order to smoothly 
coordinate services. Empirical support for IH-CBT was established in a clinical trial 
comparing mothers who received IH-CBT and concurrent home visiting with those who 
received home visiting alone (Ammerman et al., 2013). In this study, 93 mothers were first 
identified using the Edinburgh Postnatal Depression Scale (Cox et al., 1987) administered at 
three months postpartum as part of a standardized screening schedule. This was followed by 
diagnosis of MDD using a semi-structured interview. Following random assignment to 
treatment and control groups, mothers were re-assessed at post-treatment and at three-month 
follow-up. Results indicated that mothers receiving IH-CBT experienced significant benefits 
in terms of depression reduction relative to controls. Compared to those receiving home 
visiting alone, mothers in the IH-CBT condition were less likely to meet diagnostic criteria 
for MDD at post-treatment, reported fewer depressive symptoms, and obtained lower scores 
on clinician ratings of depression severity.
Mothers receiving IH-CBT also reported increased social support, improved functioning in 
day-to-day activities, and decreased psychological distress. Gains were maintained at three-
month follow-up. Findings remained when controlling for other psychiatric conditions, 
severity of MDD, therapist, home visiting model, and number of home visits. It is 
noteworthy that some mothers in the standard home visiting condition received treatment in 
the community, although as expected, this was often insufficient or ended prematurely. 
Mothers received a significantly larger dose of IH-CBT treatment than what is typically 
observed in center-based mental health settings (Hansen et al., 2002; 11.2 vs. 4.3 sessions). 
Mothers who completed all sessions of IH-CBT treatment did especially well, with 78.3% 
no longer meeting criteria for major depressive disorder at post-treatment and 90.5% 
recovered at follow-up. Mothers who recovered from depression reported increased ability to 
cope with stress related to the parenting role and more nurturing parenting of their children 
(Ammerman et al., 2014).
1.3 Study objectives
Although empirical testing documents the clinical impact of IH-CBT in depressed mothers 
in home visiting, there is a need to examine the cost-effectiveness of the treatment. The 
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purpose of a cost-effectiveness analysis is to determine if a treatment confers greater benefits 
at a given level of cost or equivalent benefits for less cost (Byford and Bower, 2002). Cost-
effectiveness analyses guide decision makers in selecting and paying for certain treatments 
over others given limited resources. Despite a broad consensus that such studies are 
important to clinical decision-making (Hill, 2012), relatively few such analyses have been 
undertaken in the treatment of depression generally (Barrett et al., 2005; Brettschneider et 
al., 2014) or for maternal depression in particular (Dennis, 2005). For cognitive behavioral 
therapy (CBT) as a treatment of depression in adults, findings have been mixed. Some 
studies have suggested that CBT is cost-effective relative to antidepressant medications, 
while others have reported the opposite finding (Barret et al., 2005). As such, determining 
the cost-effectiveness of IH-CBT is an important undertaking both in understanding its 
economic value for low-income, depressed mothers and for the field as a whole in order to 
guide selection of and payment for this treatment option.
The purpose of this study was to estimate the cost-effectiveness of IH-CBT delivered 
concurrently with home visiting compared to home visiting alone in low-income, depressed 
mothers. We hypothesized that IH-CBT would be more cost-effective than the home visiting 
in conjunction with the most commonly used treatment approach (antidepressant 
medications). Specifically, we reasoned that IH-CBT would result in decreased costs given 
its high degree of clinical effectiveness with low-income depressed mothers participating in 
home visiting. The study was performed using the perspective of the payer, Medicaid, for 
services to this population in the United States. Home visiting and access to antidepressant 
medications was assumed in the comparison cohort over a three-year time horizon. We 
performed a cost utility analysis, expressing benefits in terms of quality-adjusted life years 
gained (QALYs). An incremental cost effectiveness ratio was computed, which compared 
the change in costs divided by the change in QALYs under IH-CBT versus home visiting 
alone.
2. Methods
2.1 Study population
The study population consisted of 93 new, low-income mothers who were enrolled in a 
home visiting program and were diagnosed with MDD. [A full description of the sample and 
recruitment procedures is in Ammerman et al. (2013).] Mothers were enrolled in Every 
Child Succeeds, a community-based home visitation program serving Southwestern Ohio 
and Northern Kentucky (USA). The geographic area covered by the program included urban, 
suburban and rural areas. Two models of home visiting were utilized in this program: Nurse-
Family Partnership (NFP; Olds, 2010) and Healthy Families America (HFA; Holton and 
Harding, 2007). Participating mothers had at least one of the following demographic risk 
characteristics needed for eligibility: unmarried, low-income, ≤18 years, inadequate prenatal 
care. Mothers were enrolled in home visiting prior to 28 weeks’ gestation in NFP as per 
model parameters and from 20 weeks’ gestation through the child reaching three months of 
age for HFA. Mothers were referred from prenatal clinics, hospitals, social service agencies, 
and community physicians. In the NFP home visits were provided by nurses, while in HFA 
home visits were provided by social workers, related professionals and paraprofessionals. 
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The goals of the home visitation program were to (1) improve pregnancy outcomes through 
nutrition education and substance use reduction; (2) support parents in providing children 
with a safe, nurturing, and stimulating home environment; (3) optimize child health and 
development; (4) link families to healthcare and other needed services; and (5) promote 
economic self-sufficiency.
Mothers were young (range was 16 to 37 years, M=21.9, SD=4.8), predominantly Caucasian 
(62.4%) and African-American (32.2%), unmarried (87.1%), and low-income (76.3% <US
$20,000 annual household income). The breakdown of MDD severity was Mild = 28.0%, 
Moderate = 48.4%, and Severe = 23.6%. Onset of the presenting episode during postpartum 
(within 6 weeks after birth) was found in 29.0% of participants. Recurrent depression was 
reported by 74.2% of mothers (mean number of episodes = 2.6 (SD = 1.6), mean age of first 
episode = 15.2 years (SD = 5.1)). Comorbidity was high, with 76.1% of participants meeting 
criteria for other psychiatric disorders. The five most represented diagnoses were: PTSD = 
40.9%, Generalized Anxiety Disorder = 36.6%, Social Phobia = 30.1%, Obsessive-
Compulsive Disorder= 26.9%, Panic Disorder = 25.8%.
As part of the clinical trial, mothers were randomized to receive IH-CBT treatment delivered 
concurrently with on going home visiting (IH-CBT) or standard home visiting (SHV) alone. 
Mothers in both study arms received home visits according to the two home visiting 
approaches. Those in the SHV condition had the opportunity to receive community-based 
care and/or medication for the treatment of their MDD although few obtained or received 
adequate treatment. Mothers in the IH-CBT condition received 15 weekly sessions of 
cognitive behavioral therapy delivered in their home provided by a master’s-level therapist.
2.2 Modeling strategies
Effect sizes and results from the clinical trial were used in the economic models. The 
effectiveness measure used in the model was QALYs. QALYs represent both the quality and 
quantity of life. They are measured by a utility score where 1 represents perfect health and 0 
represents death. The utility score is multiplied by each year the mother is alive to adjust for 
the fact that mother’s quality of life is impaired when in an MDD state. The mothers in the 
model were followed for three years. A probabilistic, patient-level Markov model was 
developed using TreeAge v2014 software (TreeAge, Williamstown MA, 2016) to conduct a 
cost-utility analysis (CUA) based on the findings of Ammerman et al. (2013). Figure 1 
illustrates health state transitions in the model. Modeling strategies followed recommended 
practices by the International Society of Pharmacoeconomics and Outcomes Research and 
the Society of Medical Decision Making (Roberts et al., 2012; Siebert et al., 2012).
2.3 Parameter estimates
Patient and clinical data for IH-CBT and SHV conditions were obtained from the clinical 
trial conducted by Ammerman et al. (2013). After the treatment interval, transition 
probabilities were obtained from the published literature to estimate the likelihood of 
remaining in an MDD health state, relapsing to an MDD health state, transitioning to a 
remission health state, and dying. At every time period and in each health state, subjects may 
transition to death. These transition probabilities were summarized from a best-evidence 
Ammerman et al. Page 5
J Affect Disord. Author manuscript; available in PMC 2018 January 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
systematic literature review, described below, and applied to each cohort. Patients in MDD 
have a greater likelihood of transitioning to death to account for depression-related suicide. 
The probabilities of receiving medication and office-based treatment for MDD, 
hospitalization due to MDD, and suicide were also obtained from the published literature.
Cost data included costs of IH-CBT treatment and home visiting and costs related to medical 
care that were obtained from the Ohio Department of Medicaid (2014) where possible. It 
was augmented from the published literature when necessary from a public payer 
perspective. Health state utility information was obtained from the Medical Expenditure 
Panel Survey (MEPS) from the Agency for Healthcare Research and Quality (2015). The 
MEPS uses the EuroQoL EQ-5D, self-reported health status, and SF-12® survey 
instruments. This study employed the EQ-5D. The EQ-5D is well-suited for cost-utility 
analyses as it provides a utility score from 0 to 1, facilitating conversion of life years to 
QALYs. The utility values reflect an “at-risk” mother sample that was derived from a 
previous study delineating the health care and labor productivity costs associated with 
depression in demographically at-risk mothers (Ammerman et al., 2016).
Clinical data after the treatment intervention and cost data not available from the Ohio 
Department of Medicaid were obtained from a best-evidence systematic literature review. 
The best-evidence systematic literature review consisted of a literature search based on a-
priori inclusion and ranking criteria. The criteria included studies published in the last ten 
years, written in English, and that were clinical studies or comparative in nature. All studies 
were assessed based on their relevance to informing study parameters, validity, quality of the 
source (i.e. randomized trial vs. observational study), and recentness. The studies meeting 
these criteria were summarized using the midpoint of the reported estimates as our base 
value and the full ranges in the sensitivity analysis. Table 1 contains the parameter values 
used in the analysis and their respective sources.
2.4 Analytic strategy
The CUA estimated the incremental costs and effects of SHV + IH-CBT compared to SHV 
alone. The model simulated the transitions between the health states throughout a three-year 
time frame for the mothers. The clinical and cost parameter estimates obtained from the 
best-evidence systematic literature review were extrapolated over the three-year time frame. 
A three-year time frame was chosen because payers typically do not consider beyond a 
three-year time horizon in their decision making. Scenario analyses evaluated the impact of 
time by examining a 1-year and 5-year horizons. The future costs and outcomes were 
discounted, which emphasizes the results seen in the clinical trial. The model was designed 
to examine outcomes following the treatment period of IH-CBT. Therefore, cycle times (the 
block of time after which outcomes were observed) were set at four months. The four-month 
cycle time approximated the treatment duration of IH-CBT. Monte Carlo Simulation was 
performed to estimate the results based on 1,000 model runs drawing parameter values based 
on the parameter’s range and distribution.
To illustrate this method, let Ci and Ei denote, respectively, the costs and effects (QALYs) of 
the IH-CBT treatment, and Co and Eo denote, respectively, the costs and effects of the SHV 
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strategy. With that, the incremental cost-effectiveness ratio (ICER) for SHV + IH-CBT will 
be calculated as:
(1)
The CUA evaluated three different amounts that represent maximum thresholds an insurance 
company would be willing to pay (willingness-to-pay) for one additional QALY. These 
thresholds were US$25,000, US$50,000 and US$100,000 per QALY gained to assess the 
cost-effectiveness of SHV + IH-CBT compared to SHV. All model parameters were 
expressed as probabilities and listed as an annual rate. The model transformed the annual 
rates into four-month rates to correspond with the treatment duration of IH-CBT. The 
following formula was used to make this transformation.
(2)
where Prob is the annual probability of a given parameter to account for the four-month 
cycle.
The CUA model included costs and QALYs for both treatment arms, and used this 
information to calculate ICERs. A 3% discount rate was applied to all costs and QALYs in 
the model. The discount rate is used to determine the present value of future costs and 
clinical outcomes and is needed because costs and outcomes occur at different points in 
time. All costs were expressed in 2013 US dollars using the Medical Care Component of the 
Consumer Price Index. One- and five-year time horizons were also evaluated.
2.5 Sensitivity analysis
One-way and probabilistic sensitivity analyses were performed. One-way sensitivity 
analyses were performed to gauge the robustness and reliability of the results to changes in 
individual model input values. This sensitivity analysis thus entailed varying key model 
input values one-by-one and recalculating the ICER each time a change was made. 
Probabilistic sensitivity analysis used the model parameter ranges, distributions, and Monte 
Carlo simulation methods to recalculate the ICERs. This type of sensitivity analysis allows 
for scenarios that consider simultaneous variations in parameter values.
2.6 Model validation
The model results were validated against the published results in Ammerman et al. (2013). 
The rates of reduction in MDD for the IH-CBT and SHV conditions for the intervention and 
follow-up periods were compared at the conclusion of the first cycle and the second cycle of 
the model. The model was considered valid if the model results were within the standard 
deviation of the reported results in Ammerman et al. (2013). These time periods for 
validation corresponded with the intervention and follow-up time periods used by 
Ammerman et al. (2013).
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3. Results
Table 2 reports the results for the CUA, which assumed a base case of three-year follow up, 
as well as, one-year and five-year time horizons. In the base case model assuming a three-
year time horizon, IH-CBT was expected to be a dominant intervention compared to SHV 
alone. A dominant intervention is one that improves quality-of-life and decreases costs. In 
the three-year base case, IH-CBT was expected to improve QALYs by 0.07 QALYs 
(approximately 1 month) and reduce costs by US$2. IH-CBT was expected to be cost-
effective 99.5%, 99.7%, and 99.9% of the time for willingness-to-pay thresholds of US
$25,000, US$50,000, and US$100,000, respectively. Further, mothers receiving IH-CBT 
were expected to have 345.6 fewer days of depression relative to those receiving standard 
home visiting and treatment in the community over the three-year time horizon. Examining a 
one-year time horizon, IH-CBT was expected to have an ICER of US$9,862 and to be cost-
effective 93.6%, 99.1%, and 99.7% at willingness-to-pay thresholds of US$25,000, US
$50,000, and US$100,000, respectively. When a five-year time horizon was considered, 
SHV + IH-CBT was expected to be a dominant strategy 99.7% of the time for willingness-
to-pay thresholds of US$25,000, US$50,000, and US$100,000, respectively. Alternative 
values for the discount rate were considered to account for different rates of time preference 
because a higher (lower) discount rate places less (more) weight on future costs and benefits. 
The results of this exercise indicated that varying the discount rate from 0% to 8% did not 
materially alter the results and IH-CBT remained a cost-effective strategy.
Probabilistic sensitivity analysis was performed using a Monte Carlo simulation. The 
parameter values were randomly chosen based on their range and distribution for 1,000 
model iterations. IH-CBT was found to be a dominant strategy in 49% of the model 
iterations. Approximately 95% of the model iterations reported an ICER of less than US
$10,000/QALY for the IH-CBT treatment strategy. Figure 2 is a plot of the incremental cost 
and effectiveness result for each model iteration. Based on a willingness-to-pay threshold of 
US$25,000/QALY, over 99% of the model iterations demonstrated IH-CBT to be a cost-
effective strategy compared to SHV.
One-way sensitivity analysis was performed for key model parameters. Figure 3a 
summarizes the results for transition probabilities and healthcare utilization. Figure 3b 
summarizes the results for costs and health state utilities. As the figures reveal, IH-CBT 
remains a cost-effective strategy compared to SHV. The results were most sensitive to the 
following parameters: transition from remission to MDD, transition from MDD to 
remission, cost of MDD medications. However, the ICER for all of the parameters analyzed 
remained well below US$5,000. This finding indicated that despite uncertainty in the 
transition probabilities post treatment intervention, IH-CBT was expected to remain a highly 
cost-effective treatment.
The model was compared against the results of the clinical trial reported by Ammerman et 
al. (2013). The model matches the MDD reduction in the IH-CBT and SHV interventions. 
The model was also compared to the reported MDD diagnosis rate at the treatment follow-
up period. The model results with respect to the diagnosis of MDD were within the reported 
standard deviation of the clinical study for both intervention strategies. The differences in 
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MDD diagnosis rates were attributed to using the published literature to determine the 
transition probabilities post treatment intervention and the one-month difference between the 
follow-up period and the second cycle of the model. These differences were modest, 
indicating that the model calibrated well with the original clinical trial results.
4. Discussion
This study examined the cost-effectiveness of IH-CBT, an adapted version of CBT 
specifically designed for low-income mothers participating in home visiting programs. 
Results indicated that IH-CBT was cost-effective relative to SHV and antidepressant 
medications. Specifically, IH-CBT was expected to be cost-effective at a three-year time 
horizon 99.5%, 99.7%, and 99.9% of the time for willingness-to-pay thresholds of US
$25,000, US$50,000, and US$100,000, respectively. At the three-year time horizon, IH-CBT 
was found to improve QALYs by one month. These patterns were upheld at one-year and 
five-year time horizons. Thus, even with lower willingness-to-pay thresholds, IH-CBT 
emerges as a cost-effective program from the perspective of payers. Probabilistic sensitivity 
analyses confirmed the robustness of findings and the stability of the ICER values. Taken 
together, these findings indicate that IH-CBT is a more cost-effective treatment for low-
income, depressed mothers than current standards of practice. It is noteworthy that the added 
expense of home visiting did not offset the favorability of IH-CBT in these analyses.
The cost-effectiveness of IH-CBT was driven by the reduction in expected depression days 
resulting from treatment, nearly 346 days over the three-year time horizon. This was 
associated with decreased costs in medical care. Although home visiting by itself has limited 
impact on maternal depressive symptoms (Green et al., 2014), we have argued that the 
strong collaborative relationship between IH-CBT therapists and home visitors contributes 
to improved outcomes in depression (Ammerman et al., 2012). It is possible that this 
synergy in services is also a driver of improved cost-effectiveness. There are a number of 
additional human and financial costs (Goodman et al., 2011) associated with depression, 
including compromised maternal life course (lower educational achievement, 
unemployment) and poor child developmental outcomes (increased risk for psychiatric 
disorder, academic underachievement, use of special education services). These were not 
examined in our analyses, and future studies should seek to incorporate these into a broader 
examination of the potential cost-effectiveness and cost savings of IH-CBT and other 
treatments for depression in mothers.
Findings from this study add to the growing literature demonstrating the value of depression 
treatments specifically focused on the needs of low-income mothers. Beil et al. (2013) 
reported on a cost-effectiveness study interpersonal psychotherapy (IPT) administered to 
mothers in Early Head Start. They, too, found IPT to have favorable cost-effectiveness 
results. Our findings also add to the larger literature demonstrating the cost-effectiveness of 
CBT to adult depression in general (Barret et al., 2005; Brettschneider et al., 2014; Wiles et 
al., 2016). For example, in a systematic review of 22 studies of CBT in varied formats with 
different populations, Brettschnieder et al. concluded that most studies demonstrated 
acceptable incremental cost-utility ratios of <$50,000. Our findings compare very favorably 
with this willingness-to-pay threshold.
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IH-CBT seeks to identify mothers with depression during their participation in early 
childhood prevention programs, provide effective treatment in the home setting to reduce 
barriers to obtaining care, and leverage ongoing home visiting to optimize outcomes. This 
novel delivery system is economically sustainable from a payer perspective given its cost-
effectiveness, and adds further support for the cost utility of impactful depression treatments 
that are implemented in a focused and deliberate manner (Wang et al., 2006). Although 
many low-income mothers do not participate in home visiting programs, most receive some 
kind of social service support from other programs and organizations. Findings from this 
study suggest that using these settings to reach, screen, engage, and treat depressed mothers 
is a promising approach to make effective treatment more widely available and accessible.
The timeliness of this study is underscored by the increasing urgency to identify and 
effectively treat depressed mothers. The costs of maternal depression, to mothers and 
children, is staggering (Ammerman et al., 2016; Dagher et al., 2012). Recent research has 
confirmed the long-term deleterious outcomes of children exposed to maternal depression, 
particularly in the first years of life (Bagner et al., 2010). These consequences are amplified 
among mothers and children living in poverty (Heberle and Carter, 2015). Early 
identification and treatment of depressed mothers is an essential public health priority 
(Bauer et al., 2014). In the USA, the Affordable Care Act provides guidance and incentives 
to implement innovative outreach and treatment approaches, of which IH-CBT is a 
compelling option.
Future research should extend and expand our understanding of the economic utility of IH-
CBT in particular, and treatments for low-income, depressed mothers in general. As noted, it 
is desirable to consider the multigenerational costs associated with maternal depression by 
incorporating child outcomes. Longer follow-up of depressed mothers receiving IH-CBT 
would provide a more precise documentation of risk for relapse and course of depression. 
The cost-effectiveness of different delivery strategies is also of interest. Shorter treatment 
duration, service delivery through the internet or other electronic sources, or use of different 
levels of training of care providers might yield lower cost but equally effective interventions. 
Establishing the clinical efficacy of treatments for depression is a well-recognized essential 
step, but in a service environment in which resources are limited it is also important that 
cost-effectiveness be considered (Byford and Bower, 2002).
4.1 Study limitations
This study has some important limitations that must be noted. First, the study results are 
based on a clinical study that enrolled a relatively small number of mothers all located in the 
same region. As such, the results may not be generalizable to other home visiting programs 
due to different program methods and/or geographical considerations. Second, while the 
model attempted to capture key features of treatments and costs encountered in managing 
these mothers, some simplifying assumptions had to be made, both to render the analysis 
manageable and in recognition of data limitations. For example, mothers were assumed to 
have a constant transition probability from remission to MDD regardless of how many times 
they relapsed. Third, the clinical study of the model had a limited window of follow-up to 
assess the duration of the treatment strategies. The transition probabilities after the initial 
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treatment were obtained from the published literature. Therefore, they do not reflect the 
actual transition probabilities for the mothers in the clinical study. Thus, we had to make 
assumptions about these long-term effects and rely on sensitivity analysis to gauge the 
robustness of our findings. Future clinical studies should use a longer follow-up period to 
more precisely estimate these parameters.
4.2 Conclusion
Cost-effectiveness analyses are valuable in making decisions about which treatments to pay 
for when resources are limited. Low-income, depressed mothers are a high-risk patient 
population that incur significant costs to payers, health care providers, and employers 
(Ammerman et al., 2016). IH-CBT was developed to provide effective treatment to 
depressed mothers in home visiting programs, a population affected by poverty and 
adversity. Results from this study indicate that, in addition to its demonstrated clinical 
impact, IH-CBT is economically sound option for payers and warrants further dissemination 
and implementation.
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Highlights
• We determine the cost-effectiveness of In-Home Cognitive Behavioral 
Therapy for low-income, depressed mothers enrolled in an early 
childhood prevention program
• We use data from a the nationally-representative Medical Expenditure 
Panel Survey and the literature to determine standard of care costs
• IH-CBT was a dominant strategy and expected to be cost-effective at a 
three-year time horizon 99.5%, 99.7%, and 99.9% of the time for 
willingness-to-pay thresholds of US$25,000, US$50,000, and US
$100,000, respectively
• Over the three-year time horizon, mothers receiving IH-CBT were 
expected to have 345.6 fewer days of depression relative to those 
receiving standard home visiting and treatment in the community
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Fig. 1. 
The diagram illustrates the health states (ovals) and possible transitions between health 
states (arrows) of a mother in the model. All patients begin in the Major Depressive Disorder 
health state and can transition to the next health state based on the arrows and transition 
probabilities. Each health state has a background mortality risk based on age and can 
transition to death.
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Fig. 2. 
Plot of incremental cost-effectiveness, IH-CBT vs. SHV. This figure reports the incremental 
costs and effectiveness of each model iteration as a point on the graph. The incremental cost 
(x-axis) is the difference in costs incurred between IH-CBT and SHV treatment cohorts. The 
incremental effectiveness (y-axis) is the difference in QALYs achieved between IH-CBT and 
SHV treatment cohorts. A $25,000 willingness-to-pay (WTP) threshold limit line is plotted 
to illustrate the number of model iterations above this threshold. The ellipse represents 95% 
of all model iterations.
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Fig. 3. 
a One-way sensitivity analysis tornado diagram for health state transition probabilities and 
frequency of healthcare utilization. The tornado diagram ranks the parameters listed on the 
right in order of influence on the incremental cost-effectiveness ratio (ICER). Each 
parameter was adjusted to the low value and high value and the ICER was calculated. The 
shaded bars represent the expected ICER range for the indicated parameter. The x-axis 
reports the expected ICER. b One-way sensitivity analysis tornado diagram for costs and 
health state utility values. The tornado diagram ranks the parameters listed on the right in 
order of influence on the incremental cost-effectiveness ratio (ICER). Each parameter was 
adjusted to the low value and high value and the ICER was calculated. The shaded bars 
represent the expected ICER range for the indicated parameter. The x-axis reports the 
expected ICER value.
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